Fresenius Kabi announced the immediate availability in the U.S. of Lacosamide Injection, USP, a generic equivalent to VIMPAT. Fresenius Kabi Lacosamide Injection, USP is an approved treatment option for partial-onset seizures in patients 17 years of age and older and is available in 200 mg per 20 mL single-dose vials.
“Fresenius Kabi is pleased to provide the clinicians and patients who rely on us with high quality and accessible choices for treating patients with certain seizures,” said John Ducker, president and CEO of Fresenius Kabi USA.
Fresenius Kabi produces Lacosamide Injection, USP in the United States where the company has invested nearly $1 billion on an advanced manufacturing and distribution network dedicated to serving U.S. hospitals and health systems. To learn more about how Fresenius Kabi is strengthening America’s supply chain of care, please visit “More in America.”